Research programme: cardiac disease - Larnax

Drug Profile

Research programme: cardiac disease - Larnax

Alternative Names: Cardiac disease research programme - Larnax

Latest Information Update: 20 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Larnax (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 31 Dec 2003 Discontinued - Preclinical for Cardiovascular disorders in Germany (unspecified route)
  • 01 Apr 2003 MediGene's cardiac and metabolic disease programme has been spun off as a new company, Larnax GmbH
  • 21 Oct 2002 MediGene and Evotec OAI, as GENOVATION, have entered into an agreement to codevelop this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top